Welcome to our dedicated page for GoodRx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. filings document the financial reporting, governance, and public-company controls of a Nasdaq-listed digital healthcare platform for prescription savings. Its 8-K reports furnish quarterly operating results, revenue categories such as prescription transactions, subscriptions, and Pharma Direct, non-GAAP financial measures, and business outlook disclosures tied to medication access and pharmacy-market conditions.
GoodRx regulatory filings also cover proxy governance, board classification matters, director departures, officer appointments and resignations, executive compensation, equity awards under the 2020 Incentive Award Plan, and changes in the company’s independent registered public accounting firm.
Wagner Scott reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Scott Wagner reported an equity award of 73,434 restricted stock units (RSUs) tied to Class A common stock. The RSUs vest in full on the earlier of the one-year anniversary of June 16, 2026 or the 2027 Annual Meeting of Stockholders, subject to his continued service.
Each RSU represents a right to receive one share of Class A common stock at vesting, so this is a compensation-related grant rather than an open-market purchase. After this award, Wagner directly holds 290,097 Class A shares and is also associated with 182,900 shares held indirectly through the Wagner Family Trust.
GoodRx Holdings, Inc. Chief Accounting Officer Thomas Chan reported routine equity compensation activity involving restricted stock units that settled into Class A common stock. On June 15, 2026, he exercised RSUs representing 4,069 shares of Class A stock at a conversion price of $0.00 per share. To cover tax obligations, a total of 2,071 shares of Class A common stock were disposed of at approximately $2.65 per share through tax-withholding transactions, which are not open-market sales. The transactions reflect standard vesting and settlement of RSU awards rather than discretionary market purchases or sales.
Bezdek Trevor reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Trevor Bezdek reported an equity award and updated holdings in Class A common stock. He received 110,294 restricted stock units, each representing one share, at a price of $0.00 per unit. These restricted stock units vest 100% on December 31, 2027, subject to his continued service.
Following this grant, Bezdek holds 270,376 shares of Class A common stock directly. The filing also lists indirect holdings by grantor retained annuity trusts TB 2024-2 GRAT and TB 2025 GRAT, where he is sole trustee and annuitant, as well as JB 2024-2 GRAT and JB 2025 GRAT, which are managed by his spouse and in which he has no pecuniary interest and disclaims beneficial ownership.
Hirsch Douglas Joseph reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Douglas Joseph Hirsch reported an equity compensation grant and updated holdings in Class A common stock. On May 27, 2026, he received 4,642 deferred stock units at a price of $0.00 per share, bringing his directly held shares to 247,502.
The deferred stock units vest as to 2% of the underlying shares on May 31, 2026, with the remaining 98% vesting in substantially equal monthly installments over the following seven months. The units will settle in shares on the earliest of December 31, 2029, Separation from Service, a Change in Control, death, or Disability under the company’s Deferred Compensation Plan for Directors.
The filing also lists indirect holdings through several grantor retained annuity trusts and a spouse account. Hirsch disclaims pecuniary interest, voting, or investment control over shares held by the CH 2024-2 GRAT and CH 2025 GRAT established for his spouse.
Bruehlman Ronald E reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Ronald E. Bruehlman received a grant of 4,642 deferred stock units, each representing a contingent right to one share of Class A common stock, at no cash cost. The units vest 2% on May 31, 2026, with the remaining 98% vesting in substantially equal monthly installments over the following seven months, subject to continued service. The deferred stock units will settle upon the earliest of several events, including December 31, 2031 or separation from service. Following this grant, Bruehlman directly holds 133,918 Class A shares, including this award.
GoodRx Holdings, Inc. Chief Accounting Officer Thomas Chan reported routine equity compensation activity involving Class A common stock. On May 15, 2026, he exercised restricted stock units that converted into 5,575 shares of Class A common stock. In connection with these vestings, a total of 2,838 shares were disposed of at $2.49 per share to cover tax obligations, a non‑market, tax-withholding mechanism rather than an open-market sale. The remaining vested shares increased his directly held common stock position, while the filing notes that each restricted stock unit represents a right to receive one share of Class A common stock that vests in quarterly installments subject to continued service.
GoodRx Holdings executive Christopher A. McGinnis reported routine equity compensation activity involving restricted stock units and related tax withholding. He exercised derivative securities to acquire 44,779 shares of Class A common stock at a conversion price of $0.00 per share from restricted stock units. In a separate transaction, 19,726 shares of Class A common stock were surrendered at $2.49 per share to cover tax obligations. Following these transactions, he directly held 177,616 shares of Class A common stock. Footnotes clarify that each restricted stock unit represents a contingent right to one share of Class A common stock, with vesting scheduled over time.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 reporting a proposed sale of 43,100 shares of Common stock. The filing lists two restricted‑stock lots dated 06/03/2025 (25,852 shares) and 07/08/2025 (17,248 shares), which sum to the reported total.
The notice includes a filing date of 05/13/2026 and references NASDAQ as the market. The excerpt names the broker/dealer and the location of its financial services office.
Chan Thomas (TC) reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. reported that Chief Accounting Officer Thomas Chan received a grant of 54,494 restricted stock units (RSUs), each representing a contingent right to receive one share of Class A common stock. The award vests in 1/12 increments quarterly starting on August 15, 2026, subject to his continued service. Following the reporting date, he also held 1,000 shares of Class A common stock directly.
GoodRx Holdings, Inc. reported first-quarter 2026 revenue of $194.0 million, down from $203.0 million a year earlier, as its core prescription transactions business declined. Net income fell to $1.2 million, with net margin narrowing to 0.6% from 5.4%.
Prescription transactions revenue dropped 24% to $113.7 million, reflecting fewer Monthly Active Consumers amid pharmacy store closures and changes in an integrated savings program. Offsetting this, Pharma Direct revenue jumped 82% to $52.2 million and subscription revenue grew 16% to $24.4 million, supported by new condition-specific subscription programs.
Adjusted EBITDA was $58.3 million, giving a 30.0% Adjusted EBITDA Margin versus 34.4% a year ago, as mix shifted and costs of newer offerings rose. GoodRx ended the quarter with $235.7 million in cash and cash equivalents, a $493.8 million term loan outstanding, and continued share repurchases under its $450 million authorization.